Nesrin Gürçay
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Nesrin Gürçay has a total of 61 co-authors. Here are the top co-authors by number of shared publications:
- Mehmet Çetin
Ankara Etlik City Hospital, Department of Thoracic Surgery
5 shared publications Funda Demirağ
4 shared publications- İlTeriş Türk
Department of Thoracic Surgery, Ankara Etlik City Hospital, 06170 Ankara, Türkiye
4 shared publications - Necati Solak
Department of Thoracic Surgery, Ankara Etlik City Hospital, Ankara, Turkiye
4 shared publications - Pınar Bıçakçıoğlu
Thoracic Surgery Department, Ankara Atatürk Sanatoryum Eğitim ve Araştırma Hastanesi, Ankara, Türkiye
4 shared publications - Selim Şakir Erkmen Gülhan
Thoracic Surgery Department, Ankara Atatürk Sanatoryum Eğitim ve Araştırma Hastanesi, Ankara, Türkiye
3 shared publications
Latest Publications
- Open Access
- 29 July 2026
- Published by Galenos Yayinevi in Acta Haematologica Oncologica Turcica
Diagnostic Contribution of Mucicarmine Staining in TTF-1- and p40-negative Non-small Cell Lung Carcinoma Diagnosed on Small Biopsy Specimens
Diagnostic Contribution of Mucicarmine Staining in TTF-1- and p40-negative Non-small Cell Lung Carcinoma Diagnosed on Small Biopsy Specimens - Acta Haematologica Oncologica Turcica
- 29 July 2026
- Published by Galenos Yayinevi in Acta Haematologica Oncologica Turcica
Open AccessDiagnostic Contribution of Mucicarmine Staining in TTF-1- and p40-negative Non-small Cell Lung Carcinoma Diagnosed on Small Biopsy Specimens
Diagnostic Contribution of Mucicarmine Staining in TTF-1- and p40-negative Non-small Cell Lung Carcinoma Diagnosed on Small Biopsy Specimens - Acta Haematologica Oncologica Turcica
- Open Access
- 4 July 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (13) , 5236
KRAS Mutation Subtypes, Co-Mutations, PD-L1 Expression, and Survival Outcomes in Non-Small Cell Lung Cancer
Background: KRAS mutations are among the most common oncogenic drivers in non-small cell lung cancer (NSCLC) and are associated with substantial molecular and immunological heterogeneity. However, the clinicopathological associations and prognostic relevance of KRAS mutation subtypes and co-occurring genomic alterations in relation to PD-L1 expression and survival outcomes remain incompletely understood, particularly in the immunotherapy era. Methods: This retrospective single-center study included 93 KRAS-mutant NSCLC patients identified among 543 consecutively sequenced cases between March 2024 and March 2025. KRAS mutation subtypes, co-mutations involving TP53, STK11, and KEAP1, PD-L1 expression status, clinicopathological features, and survival outcomes were evaluated. Overall survival was assessed using Kaplan–Meier analysis and Cox proportional hazards regression models. Results: KRAS mutations were detected in 17.1% of NSCLC patients. G12C was the most frequent KRAS subtype (38.7%), followed by G12V (18.3%) and G12D (14.0%). Co-occurring mutations were identified in 73.1% of cases, most commonly involving TP53 (40.9%) and STK11 (33.3%). PD-L1 expression was negative in 48.4% of patients, low in 28.0%, and high in 23.7%. No significant association was identified between KRAS mutation subtype and PD-L1 expression (p = 0.663). STK11-mutated tumors demonstrated a trend toward lower PD-L1 expression levels compared with STK11 wild-type tumors. However, none of the molecular variables retained independent prognostic significance. Immunotherapy was associated with significantly prolonged overall survival (median OS: 24 vs. 7 months, p = 0.013) and remained independently associated with improved survival in multivariate analysis (HR: 0.376, 95% CI: 0.204–0.694, p = 0.002). Advanced-stage disease independently predicted worse survival outcomes (HR: 13.43, 95% CI: 1.81–99.79, p = 0.011). Conclusions: KRAS mutation subtypes and co-occurring genomic alterations demonstrated limited independent prognostic significance in this real-world NSCLC cohort. In contrast, immunotherapy was associated with improved overall survival in this retrospective cohort. These findings should be interpreted as observational and hypothesis-generating rather than evidence of predictive treatment benefit. Larger prospective studies integrating genomic and immune biomarkers are warranted.
- 4 July 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (13) , 5236
Open AccessKRAS Mutation Subtypes, Co-Mutations, PD-L1 Expression, and Survival Outcomes in Non-Small Cell Lung Cancer
Background: KRAS mutations are among the most common oncogenic drivers in non-small cell lung cancer (NSCLC) and are associated with substantial molecular and immunological heterogeneity. However, the clinicopathological associations and prognostic relevance of KRAS mutation subtypes and co-occurring genomic alterations in relation to PD-L1 expression and survival outcomes remain incompletely understood, particularly in the immunotherapy era. Methods: This retrospective single-center study included 93 KRAS-mutant NSCLC patients identified among 543 consecutively sequenced cases between March 2024 and March 2025. KRAS mutation subtypes, co-mutations involving TP53, STK11, and KEAP1, PD-L1 expression status, clinicopathological features, and survival outcomes were evaluated. Overall survival was assessed using Kaplan–Meier analysis and Cox proportional hazards regression models. Results: KRAS mutations were detected in 17.1% of NSCLC patients. G12C was the most frequent KRAS subtype (38.7%), followed by G12V (18.3%) and G12D (14.0%). Co-occurring mutations were identified in 73.1% of cases, most commonly involving TP53 (40.9%) and STK11 (33.3%). PD-L1 expression was negative in 48.4% of patients, low in 28.0%, and high in 23.7%. No significant association was identified between KRAS mutation subtype and PD-L1 expression (p = 0.663). STK11-mutated tumors demonstrated a trend toward lower PD-L1 expression levels compared with STK11 wild-type tumors. However, none of the molecular variables retained independent prognostic significance. Immunotherapy was associated with significantly prolonged overall survival (median OS: 24 vs. 7 months, p = 0.013) and remained independently associated with improved survival in multivariate analysis (HR: 0.376, 95% CI: 0.204–0.694, p = 0.002). Advanced-stage disease independently predicted worse survival outcomes (HR: 13.43, 95% CI: 1.81–99.79, p = 0.011). Conclusions: KRAS mutation subtypes and co-occurring genomic alterations demonstrated limited independent prognostic significance in this real-world NSCLC cohort. In contrast, immunotherapy was associated with improved overall survival in this retrospective cohort. These findings should be interpreted as observational and hypothesis-generating rather than evidence of predictive treatment benefit. Larger prospective studies integrating genomic and immune biomarkers are warranted.
- Open Access
- 14 October 2025
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 55 (5) , 1151-1160
Impact of pulmonary metastasectomy timing and nodule characteristics on survival outcomes in patients with pediatric sarcoma
Background/aim: Pulmonary metastasectomy (PM) is a crucial intervention for patients with metastatic sarcomas, particularly among pediatric populations. The timing of PM and its impact on survival outcomes remain a subject of debate in the literature. This study aims to evaluate the impact of PM on survival outcomes. Materials and methods: This retrospective study included pediatric patients diagnosed with sarcomas who underwent pulmonary metastasectomy. Demographic and clinical characteristics, including age, sex, primary malignancy type, metastasis presence at diagnosis, chemotherapy response, and PM details (e.g., number and laterality of metastatic nodules, time from metastasis detection to surgery) were analyzed. Survival data were assessed using Kaplan–Meier curves and Cox regression analysis, and statistical significance was determined using log-rank tests. Results: A total of 29 patients (51.7% male, 48.3% female) were included, with 55.2% presenting with metastasis at diagnosis. Overall, 47 surgical procedures were performed. The 5-year survival rate following PM was significantly higher for patients who underwent surgery within 30 days of metastasis detection (75.26%) compared to those who had surgery later (35.88%, p = 0.031). In univariate analysis, both 5-year survival after nodule detection and 5-year survival after metastasectomy were better in patients who underwent PM within the first 30 days (p = 0.022 and p = 0.039, respectively). Additionally, the number of metastatic nodules (< 10 versus ≥ 10) and the number of nodules per operation (< 3 versus ≥ 3) were significant factors influencing survival. Patients with fewer metastatic nodules exhibited better 5-year survival rates. The survival outcomes were comparable across different sarcoma subtypes, including osteosarcoma, Ewing sarcoma, and synovial sarcoma. Conclusion: Our study suggests that early pulmonary metastasectomy, performed within 30 days of metastasis detection, improves 5-year survival in pediatric sarcoma patients. The number of metastatic nodules and the timing of surgery are critical factors in determining survival outcomes. These findings highlight the importance of timely surgical intervention and careful evaluation of metastasis extent in optimizing patient prognosis.
- 14 October 2025
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 55 (5) , 1151-1160
Open AccessImpact of pulmonary metastasectomy timing and nodule characteristics on survival outcomes in patients with pediatric sarcoma
Background/aim: Pulmonary metastasectomy (PM) is a crucial intervention for patients with metastatic sarcomas, particularly among pediatric populations. The timing of PM and its impact on survival outcomes remain a subject of debate in the literature. This study aims to evaluate the impact of PM on survival outcomes. Materials and methods: This retrospective study included pediatric patients diagnosed with sarcomas who underwent pulmonary metastasectomy. Demographic and clinical characteristics, including age, sex, primary malignancy type, metastasis presence at diagnosis, chemotherapy response, and PM details (e.g., number and laterality of metastatic nodules, time from metastasis detection to surgery) were analyzed. Survival data were assessed using Kaplan–Meier curves and Cox regression analysis, and statistical significance was determined using log-rank tests. Results: A total of 29 patients (51.7% male, 48.3% female) were included, with 55.2% presenting with metastasis at diagnosis. Overall, 47 surgical procedures were performed. The 5-year survival rate following PM was significantly higher for patients who underwent surgery within 30 days of metastasis detection (75.26%) compared to those who had surgery later (35.88%, p = 0.031). In univariate analysis, both 5-year survival after nodule detection and 5-year survival after metastasectomy were better in patients who underwent PM within the first 30 days (p = 0.022 and p = 0.039, respectively). Additionally, the number of metastatic nodules (< 10 versus ≥ 10) and the number of nodules per operation (< 3 versus ≥ 3) were significant factors influencing survival. Patients with fewer metastatic nodules exhibited better 5-year survival rates. The survival outcomes were comparable across different sarcoma subtypes, including osteosarcoma, Ewing sarcoma, and synovial sarcoma. Conclusion: Our study suggests that early pulmonary metastasectomy, performed within 30 days of metastasis detection, improves 5-year survival in pediatric sarcoma patients. The number of metastatic nodules and the timing of surgery are critical factors in determining survival outcomes. These findings highlight the importance of timely surgical intervention and careful evaluation of metastasis extent in optimizing patient prognosis.
- 28 September 2025
- Published by Archives of Current Medical Research in Archives of Current Medical Research
- Vol. 6 (3) , 209-215
Anterior Mediastinotomy: Is it Still a Reliable Diagnostic Method in the Era of Minimally Invasive Techniques? – A Retrospective Analysis of 73 Cases
Background: Rapid diagnosis of anterior mediastinal masses, which can arise from a wide range of diseases, is crucial for adopting appropriate treatment approaches. Methods: The demographic, radiological, operative, and pathological data of 73 patients who underwent diagnostic procedures—computed tomography (CT)-guided transthoracic fine-needle aspiration biopsy (TTFNAB), anterior mediastinotomy (AM), or video-assisted thoracoscopic surgery (VATS)—for anterior mediastinal masses between 2013 and 2023 were retrospectively analyzed. Results: The mean age of the patients was 45.29±18.51 years (range: 9–82), and 40 (54.8%) were male. The most common presenting symptom was chest pain (33%), while incidental detection occurred in 23.3% of cases. Initial biopsy procedures yielded a pathological diagnosis in 90.4% of cases, with lymphoma being the most common diagnosis (42.4%). Compared to surgical biopsies, TTFNAB had significantly lower diagnostic yield and shorter hospital stay but was performed in significantly older patients (p=0.025, p
- 28 September 2025
- Published by Archives of Current Medical Research in Archives of Current Medical Research
- Vol. 6 (3) , 209-215
Anterior Mediastinotomy: Is it Still a Reliable Diagnostic Method in the Era of Minimally Invasive Techniques? – A Retrospective Analysis of 73 Cases
Background: Rapid diagnosis of anterior mediastinal masses, which can arise from a wide range of diseases, is crucial for adopting appropriate treatment approaches. Methods: The demographic, radiological, operative, and pathological data of 73 patients who underwent diagnostic procedures—computed tomography (CT)-guided transthoracic fine-needle aspiration biopsy (TTFNAB), anterior mediastinotomy (AM), or video-assisted thoracoscopic surgery (VATS)—for anterior mediastinal masses between 2013 and 2023 were retrospectively analyzed. Results: The mean age of the patients was 45.29±18.51 years (range: 9–82), and 40 (54.8%) were male. The most common presenting symptom was chest pain (33%), while incidental detection occurred in 23.3% of cases. Initial biopsy procedures yielded a pathological diagnosis in 90.4% of cases, with lymphoma being the most common diagnosis (42.4%). Compared to surgical biopsies, TTFNAB had significantly lower diagnostic yield and shorter hospital stay but was performed in significantly older patients (p=0.025, p
- 23 September 2025
- Published by Elsevier in Seminars in Thoracic and Cardiovascular Surgery
- Vol. 38 (3) , 223-229
Prognostic Impact of Clinicopathological and Inflammatory Markers in Surgically Treated Pulmonary Invasive Mucinous Adenocarcinoma
- 23 September 2025
- Published by Elsevier in Seminars in Thoracic and Cardiovascular Surgery
- Vol. 38 (3) , 223-229
Prognostic Impact of Clinicopathological and Inflammatory Markers in Surgically Treated Pulmonary Invasive Mucinous Adenocarcinoma
- Open Access
- 4 July 2025
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 25 (1) , 1-9
18F-FDG PET/CT SUVmax in pleuropulmonary solitary fibrous tumors: can it be incorporated into risk classification systems for predicting recurrence?
Background: Several studies have been conducted to identify the parameters associated with the aggressive course of pleuropulmonary solitary fibrous tumors (SFT) following surgical treatment, and various classification systems have been proposed for assessing risk. Methods: The surgical outcomes of patients with pleuropulmonary SFT who underwent surgery between 2009 and 2024 at our center were retrospectively evaluated. Parameters of patients who experienced recurrence during follow-up were analyzed, and the risk classification systems proposed by Demicco were tested on our patient cohort. The pozitron emision tomography/ computed tomography (PET/CT) standart uptake value(SUVmax), which was significantly associated with recurrence, was incorporated into the modified Demicco classification, and a new classification model was developed and compared with existing models. Results: Among the 79 included patients, 21.5% had intraparenchymal tumors, which were excised along with various parenchymal resections, while pleural tumors underwent mass excision. The postoperative follow-up period was 108.16 ± 44.09 months, during which 7.6% of patients experienced recurrence. Tumor size (p = 0.023), mitotic index (p < 0.001), presence of necrosis (p = 0.007), and PET/CT SUVmax value (p = 0.005) were found to be significantly associated with recurrence. The PET/CT SUVmax value, which was not included in Demicco’s classifications, ranged from 1.12 to 7.98, with a cutoff value of 4.50. The addition of SUVmax to the modified Demicco classification categorized all patients with recurrence into the high-risk group, and the new classification model strongly differentiated recurrence (p < 0.01, 100% sensitivity, 71.43% specificity). Conclusion: The incorporation of SUVmax into the modified Demicco classification system for pleuropulmonary SFT provides a more significant prediction of recurrence.
- 4 July 2025
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 25 (1) , 1-9
Open Access18F-FDG PET/CT SUVmax in pleuropulmonary solitary fibrous tumors: can it be incorporated into risk classification systems for predicting recurrence?
Background: Several studies have been conducted to identify the parameters associated with the aggressive course of pleuropulmonary solitary fibrous tumors (SFT) following surgical treatment, and various classification systems have been proposed for assessing risk. Methods: The surgical outcomes of patients with pleuropulmonary SFT who underwent surgery between 2009 and 2024 at our center were retrospectively evaluated. Parameters of patients who experienced recurrence during follow-up were analyzed, and the risk classification systems proposed by Demicco were tested on our patient cohort. The pozitron emision tomography/ computed tomography (PET/CT) standart uptake value(SUVmax), which was significantly associated with recurrence, was incorporated into the modified Demicco classification, and a new classification model was developed and compared with existing models. Results: Among the 79 included patients, 21.5% had intraparenchymal tumors, which were excised along with various parenchymal resections, while pleural tumors underwent mass excision. The postoperative follow-up period was 108.16 ± 44.09 months, during which 7.6% of patients experienced recurrence. Tumor size (p = 0.023), mitotic index (p < 0.001), presence of necrosis (p = 0.007), and PET/CT SUVmax value (p = 0.005) were found to be significantly associated with recurrence. The PET/CT SUVmax value, which was not included in Demicco’s classifications, ranged from 1.12 to 7.98, with a cutoff value of 4.50. The addition of SUVmax to the modified Demicco classification categorized all patients with recurrence into the high-risk group, and the new classification model strongly differentiated recurrence (p < 0.01, 100% sensitivity, 71.43% specificity). Conclusion: The incorporation of SUVmax into the modified Demicco classification system for pleuropulmonary SFT provides a more significant prediction of recurrence.
- 17 March 2024
- Published by Springer Nature in Updates in Surgery
- Vol. 76 (6) , 2303-2311
Are precautions actually a risk factor in the development of bronchopleural fistula after pneumonectomy? A retrospective analysis of 299 cases
Purpose Bronchopleural fistula most commonly occurs after pneumonectomies, with high morbidity and mortality. A preventive approach is essential. Risk factors can be classified depending on the patient, anatomy, surgical technique, and other causes. Methods Patients (n = 370) who underwent pneumonectomy between 2010 and 2020 were evaluated. The digital media and archive files of the patients (n = 299) were reviewed retrospectively. Results While 271 patients (90.6%) were male, 28 (9.4%) were female. The mean age was 56.63 years. The bronchopleural fistula rate was 14.7% (44/299). Serum protein deficiency, right pneumonectomy, completion pneumonectomy, bronchial manual suturing, advanced stage, prolongation of time after neoadjuvant therapy, length of drain and hospital stay, tissue support for the stump, and short bronchial stump were significant for bronchopleural fistula. Smoking in patients operated on for malignancy and low serum albumin value in benign and chronic infectious diseases were significant in terms of fistula. In patients who developed bronchopleural fistula, the 5-year survival rate was 18.4%. Conclusion The most important risk factors in bronchopleural fistula depend on the surgical technique and so are completely preventable. Contrary to the literature, short stump and tissue support to the stump were found to be risk factors for fistula. In addition, the effect of the time between neoadjuvant therapy and operation should be examined in further studies.
- 17 March 2024
- Published by Springer Nature in Updates in Surgery
- Vol. 76 (6) , 2303-2311
Are precautions actually a risk factor in the development of bronchopleural fistula after pneumonectomy? A retrospective analysis of 299 cases
Purpose Bronchopleural fistula most commonly occurs after pneumonectomies, with high morbidity and mortality. A preventive approach is essential. Risk factors can be classified depending on the patient, anatomy, surgical technique, and other causes. Methods Patients (n = 370) who underwent pneumonectomy between 2010 and 2020 were evaluated. The digital media and archive files of the patients (n = 299) were reviewed retrospectively. Results While 271 patients (90.6%) were male, 28 (9.4%) were female. The mean age was 56.63 years. The bronchopleural fistula rate was 14.7% (44/299). Serum protein deficiency, right pneumonectomy, completion pneumonectomy, bronchial manual suturing, advanced stage, prolongation of time after neoadjuvant therapy, length of drain and hospital stay, tissue support for the stump, and short bronchial stump were significant for bronchopleural fistula. Smoking in patients operated on for malignancy and low serum albumin value in benign and chronic infectious diseases were significant in terms of fistula. In patients who developed bronchopleural fistula, the 5-year survival rate was 18.4%. Conclusion The most important risk factors in bronchopleural fistula depend on the surgical technique and so are completely preventable. Contrary to the literature, short stump and tissue support to the stump were found to be risk factors for fistula. In addition, the effect of the time between neoadjuvant therapy and operation should be examined in further studies.
- 2 August 2023
- Published by Elsevier in Annals of Diagnostic Pathology
- Vol. 66, 152188
High grade tumor budding is associated with poor survival in pathologic stage I lung adenocarcinoma
- 2 August 2023
- Published by Elsevier in Annals of Diagnostic Pathology
- Vol. 66, 152188
High grade tumor budding is associated with poor survival in pathologic stage I lung adenocarcinoma
- 31 May 2022
- Published by Archives of Current Medical Research in Archives of Current Medical Research
Tuberculosis mimicking Rhabdomyosarcoma Metastasis in a pediatric patient
In childhood sarcomas, the lung is one of the most common organs where metastasis occurs. Immunosuppression caused by antineoplastic treatments for primary cancer may facilitate the reactivation of latent tuberculosis (TB) infection, which can mimic cancer metastasis. The thought of lung metastasis is an important entity that changes the follow-up and treatment approach. Evaluating TB in initial differential diagnosis can prevent unjustifiable chemoradiotherapy and surgery. In this case report, we submit a 2-years-old boy under follow up of alveolar type rhabdomyosarcoma in masseter muscle also received chemoradiotherapy with a pre-diagnosis of lung metastasis patient who underwent surgical resection when the treatment didn’t produce any benefit and all of the 34 excised nodules from the right lung were reported as “granulomatous inflammation suggestive of TB.”
- 31 May 2022
- Published by Archives of Current Medical Research in Archives of Current Medical Research
Tuberculosis mimicking Rhabdomyosarcoma Metastasis in a pediatric patient
In childhood sarcomas, the lung is one of the most common organs where metastasis occurs. Immunosuppression caused by antineoplastic treatments for primary cancer may facilitate the reactivation of latent tuberculosis (TB) infection, which can mimic cancer metastasis. The thought of lung metastasis is an important entity that changes the follow-up and treatment approach. Evaluating TB in initial differential diagnosis can prevent unjustifiable chemoradiotherapy and surgery. In this case report, we submit a 2-years-old boy under follow up of alveolar type rhabdomyosarcoma in masseter muscle also received chemoradiotherapy with a pre-diagnosis of lung metastasis patient who underwent surgical resection when the treatment didn’t produce any benefit and all of the 34 excised nodules from the right lung were reported as “granulomatous inflammation suggestive of TB.”
- Open Access
- 10 May 2022
- Published by Springer Nature in Cureus
- Vol. 14 (5) , e24884
The Differentiation of Metastatic Mediastinal Lymph Nodes From Benign Hypermetabolic Lesions
Anthracosis may cause a positron emission tomography/computed tomography (PET/CT) false positivity in mediastinal and hilar lymph nodes. We aimed to evaluate the radiological features and the maximum standardized uptake values (SUVmax) of the mediastinal lymph nodes with anthracosis or squamous cell lung cancer metastasized. Patients diagnosed with anthracosis or squamous cell lung cancer with endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) between January 1, 2015, and November 15, 2020, in a tertiary hospital were enrolled. The squamous cell subtype of lung cancer was selected due to its association with tobacco use, biomass, and air pollution. Anthracosis may occur due to the same etiologic reasons. A total of 190 patients met the study enrollment criteria, of which 86 were diagnosed with anthracosis and 33 with squamous cell lung cancer lymph metastasis. Median values for short axis, long axis, SUVmax, shape features, and presence of calcification were found significantly different between the groups. In receiver operating characteristic (ROC) analysis, the SUVmax cut-off value was calculated as 6.61. With this cutoff value, the negative predictive value (NPV) was 92.5% and the positive predictive value (PPV) was 54% for differentiating anthracosis and malignant lymph nodes metastasis. We conclude that the evaluation of the shape and metabolic activities of the anthracotic lymph nodes detected by PET/CT together with EBUS-TBNA granted a more accurate staging of the patients and more cancer patients will benefit from surgical treatment.
- 10 May 2022
- Published by Springer Nature in Cureus
- Vol. 14 (5) , e24884
Open AccessThe Differentiation of Metastatic Mediastinal Lymph Nodes From Benign Hypermetabolic Lesions
Anthracosis may cause a positron emission tomography/computed tomography (PET/CT) false positivity in mediastinal and hilar lymph nodes. We aimed to evaluate the radiological features and the maximum standardized uptake values (SUVmax) of the mediastinal lymph nodes with anthracosis or squamous cell lung cancer metastasized. Patients diagnosed with anthracosis or squamous cell lung cancer with endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) between January 1, 2015, and November 15, 2020, in a tertiary hospital were enrolled. The squamous cell subtype of lung cancer was selected due to its association with tobacco use, biomass, and air pollution. Anthracosis may occur due to the same etiologic reasons. A total of 190 patients met the study enrollment criteria, of which 86 were diagnosed with anthracosis and 33 with squamous cell lung cancer lymph metastasis. Median values for short axis, long axis, SUVmax, shape features, and presence of calcification were found significantly different between the groups. In receiver operating characteristic (ROC) analysis, the SUVmax cut-off value was calculated as 6.61. With this cutoff value, the negative predictive value (NPV) was 92.5% and the positive predictive value (PPV) was 54% for differentiating anthracosis and malignant lymph nodes metastasis. We conclude that the evaluation of the shape and metabolic activities of the anthracotic lymph nodes detected by PET/CT together with EBUS-TBNA granted a more accurate staging of the patients and more cancer patients will benefit from surgical treatment.